Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: A CALGB 40503 (Alliance) correlative study.
- Citation:
- Breast Cancer Res Treat vol 171 (2) 325-34
- Year:
- 2018
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 8
- Parents:
- 2469
- Children:
- None
- Program:
- CCP
- Primary Committee:
- Older Adult
- Sec. Committees:
- Breast Health Outcomes
- Pharmas:
- Grants:
- UG1CA189823, 30CA033572, U10CA180790, U10CA180795, U10CA180820, CA180795, U10CA180836, U10CA180838, U10CA180857, U10CA180858, U10CA180867, U10CA180888, CA180858
- Corr. Author:
- Authors:
- Daneng Li Linda M. McCall Olwen M Hahn Clifford A. Hudis Harvey J. Cohen Hyman B. Muss Aminah Jatoi Jacqueline M. Lafky Karla V. Ballman Eric P. Winer Debu Tripathy Bryan Schneider William Barry Maura N. Dickler Arti Hurria
- Networks:
- CA043, LAPS-CT018, LAPS-IL057, LAPS-MN026, LAPS-NC007, LAPS-NC010, LAPS-NY016, LAPS-TX035, NY018
- Study
- CALGB-40503
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: